Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.51 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10308404 | 0.90 | CTSS (0.54) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL30759429 | 0.86 | CYP1A2 (0.47) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL29727304 | 0.86 | CYP1A2 (0.47) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL17446797 | 0.83 | CTSS (0.53) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL30900200 | 0.81 | CYP1A2 (0.54) | CTSKCTSSPSENENCTSL | |
| SCHEMBL29488040 | 0.81 | CYP1A2 (0.54) | CTSKCTSSPSENENCTSL | |
| SCHEMBL29051024 | 0.81 | CYP1A2 (0.54) | CTSKCTSSPSENENCTSL | |
| SCHEMBL29051026 | 0.81 | CYP1A2 (0.54) | CTSKCTSSPSENENCTSL | |
| SCHEMBL10144106 | 0.81 | PSENEN (0.45) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL29558421 | 0.80 | CTSS (0.56) | CTSKCTSSCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | CTSK 3162/4885CTSS 2203/4885PSENEN 1747/4885 |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | CTSK 3162/4885CTSS 2203/4885PSENEN 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.